Repligen (RGEN) Scheduled to Post Quarterly Earnings on Tuesday

Repligen (NASDAQ:RGEN) will be posting its quarterly earnings results before the market opens on Tuesday, November 12th. Analysts expect Repligen to post earnings of $0.34 per share for the quarter. Parties interested in participating in the company’s conference call can do so using this link.

Repligen Price Performance

RGEN traded up $4.50 during trading hours on Tuesday, hitting $144.03. The company’s stock had a trading volume of 175,748 shares, compared to its average volume of 656,311. The business’s 50-day moving average price is $141.90 and its 200-day moving average price is $145.60. Repligen has a 12 month low of $113.50 and a 12 month high of $211.13. The company has a current ratio of 6.65, a quick ratio of 5.56 and a debt-to-equity ratio of 0.26.

Analyst Upgrades and Downgrades

Several brokerages have weighed in on RGEN. Wells Fargo & Company assumed coverage on Repligen in a research note on Tuesday, August 27th. They set an “overweight” rating and a $180.00 price objective on the stock. Royal Bank of Canada restated an “outperform” rating and set a $205.00 price target on shares of Repligen in a report on Thursday, September 26th. UBS Group lowered their target price on shares of Repligen from $205.00 to $185.00 and set a “buy” rating for the company in a report on Wednesday, July 31st. Stephens reissued an “overweight” rating and issued a $170.00 price objective on shares of Repligen in a research report on Tuesday, July 30th. Finally, JPMorgan Chase & Co. boosted their target price on Repligen from $190.00 to $200.00 and gave the company an “overweight” rating in a research report on Wednesday, July 31st. Two equities research analysts have rated the stock with a hold rating and eight have given a buy rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $190.25.

Insider Buying and Selling

In related news, Director Anthony Hunt sold 22,191 shares of the company’s stock in a transaction that occurred on Tuesday, September 10th. The stock was sold at an average price of $145.37, for a total value of $3,225,905.67. Following the sale, the director now owns 139,840 shares of the company’s stock, valued at approximately $20,328,540.80. This represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders own 1.20% of the company’s stock.

About Repligen

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.